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Abstract
Background—Heart failure disease management programs can influence medical resource use
and quality-adjusted survival. Because projecting long-term costs and survival is challenging, a
consistent and valid approach to extrapolating short-term outcomes would be valuable.
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Methods—We developed the Tools for Economic Analysis of Patient Management Interventions
in Heart Failure (TEAM-HF) Cost-Effectiveness Model, a Web-based simulation tool designed to
integrate data on demographic, clinical, and laboratory characteristics, use of evidence-based
medications, and costs to generate predicted outcomes. Survival projections are based on a
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modified Seattle Heart Failure Model (SHFM). Projections of resource use and quality of life are
modeled using relationships with time-varying SHFM scores. The model can be used to evaluate
parallel-group and single-cohort designs and hypothetical programs. Simulations consist of 10,000
pairs of virtual cohorts used to generate estimates of resource use, costs, survival, and incremental
cost-effectiveness ratios from user inputs.
Results—The model demonstrated acceptable internal and external validity in replicating
resource use, costs, and survival estimates from 3 clinical trials. Simulations to evaluate the costeffectiveness of heart failure disease management programs across 3 scenarios demonstrate how
the model can be used to design a program in which short-term improvements in functioning and
use of evidence-based treatments are sufficient to demonstrate good long-term value to the health
care system.

Author Manuscript

Conclusion—The TEAM-HF Cost-Effectiveness Model provides researchers and providers with
a tool for conducting long-term cost-effectiveness analyses of disease management programs in
heart failure.

Introduction

Author Manuscript

Although economic evaluations of heart failure disease management programs are plentiful,
a recent review identified only 2 formal cost-effectiveness analyses that extrapolated beyond
a trial’s follow-up period.1 Without extrapolation, the value of a disease management
program may be underestimated. For example, an analysis of the South Texas Congestive
Heart Failure Disease Management Project reported an incremental cost-effectiveness ratio
greater than $100,000 per quality-adjusted life-year (QALY) within the trial’s 18-month
follow-up period.2 However, extension of the time horizon with a Markov model structured
using New York Heart Association (NYHA) classification reduced the incremental costeffectiveness ratio to less than $50,000 per QALY.3 This example demonstrates the
importance of accounting for all downstream costs and health benefits attributable to an
intervention to provide a fair assessment of its cost-effectiveness.

Author Manuscript

With support from the National Institute of Nursing Research, we developed user-friendly
tools to facilitate high-quality economic evaluations of patient-focused interventions. In our
project, Tools for Economic Analysis of Patient Management Interventions in Heart Failure
(TEAM-HF), we developed a costing tool4 and a cost-effectiveness model. In this paper, we
describe the TEAM-HF Cost-Effectiveness Model, a generalizable, Web-based tool
designed to assist researchers, administrators, and providers in estimating short-term or
long-term estimates of resource use, costs, and cost-effectiveness of disease management
programs or other care strategies in heart failure. We then compare predicted estimates of
resource use and costs from the model to estimates from 3 studies to evaluate the internal
and external validity of the model. We also evaluate the potential cost-effectiveness of 3
disease management scenarios to demonstrate how the model can be used to design more
cost-effective interventions.
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Methods
Web-Based Application
To maximize accessibility, we developed a freely available Web-based tool that allows users
to select modeling options and specify inputs in an integrated simulation model. The tool
takes the form of a series of input pages (Table 1). It includes 3 study design options:
hypothetical scenario; parallel groups; and single cohort (Supplemental Figure A).

Author Manuscript

The hypothetical scenario design option allows the user to generate simulated outcomes for
2 patient groups with different clinical and treatment characteristics. The parallel groups
design option is appropriate for randomized trials or other studies with 2 comparator groups.
The user prescribes observed counts of resource use and deaths for the observed follow-up
period. After the observation period, simulated outcomes are generated over the time period
specified by the user. The single cohort design option allows users to evaluate a program
that has already been implemented. The user prescribes clinical and treatment characteristics
for the patients before and after their participation in the program.
Additional input pages correspond to patients’ demographic and clinical characteristics,
laboratory test results, use of diuretics, and use of evidence-based medications and devices
that represent parameters in the prognostic model integrated with the tool. The user can also
prescribe unit costs for medications, hospitalizations, emergency department visits, and
outpatient visits.

Author Manuscript

A cost-effectiveness analysis requires users to account for the costs associated with a disease
management program. Therefore, the user must specify the duration and monthly cost of the
program. If the program includes an “intense” phase and a less intense “maintenance” phase,
the user can specify the duration and monthly cost for each phase. The user can also extend
the monthly costs of the program indefinitely (ie, until death). The final inputs relate to the
time horizon for the simulations, discount rates, and options for reporting.
Model Structure
We selected the Seattle Heart Failure Model (SHFM) as the underlying prognostic model,
because its external validity has been tested in 14 clinical cohorts, more than any other
model for heart failure.5,6 Also, its inclusion of multiple clinical and laboratory variables
and the integration of treatment effects for evidence-based therapies allows our model to
account for the effects of disparate disease management programs or treatment care
strategies. For example, the same model could be used to evaluate a program to improve
physical functioning or a program to increase the use of β-blockers.

Author Manuscript

Modifications to the SHFM
In the original SHFM publication, an exponential hazard function was suggested to generate
long-term survival estimates.5 An exponential hazard function assumes a constant mortality
rate, which can lead to overestimation of survival. Therefore, we replaced the exponential
function with a calibrated competing risks regression model in which the baseline hazard for
each mode of death was assumed to follow a Gompertz distribution, under the proportional
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hazards assumption, using data representing 7151 patients from 4 clinical trials and
prospective observational cohorts.6 The shape parameters for heart failure death and non–
heart failure death were positive (0.281 and 0.204, respectively), indicating increasing risk
over time, whereas the parameter for sudden death was approximately equal to zero (< .001),
indicating constant risk. The fitted survival model enables us to calculate expected survival
time for any SHFM score. Figure 1 shows the overall survival curves for integer SHFM
scores; the corresponding table displays the mean survival estimates. See the Online-Only
Supplement for details.

Author Manuscript

We also modified the treatment effects of several medication classes in the SHFM. First, we
removed the effect of statins on mortality risk to reflect findings from 2 clinical trials.7,8
Second, although meta-analyses support the benefits of angiotensin-converting enzyme
(ACE) inhibitors and angiotensin II receptor blockers (ARBs) in heart failure, clinical trials
have not demonstrated additive treatment effects of ARBs with ACE inhibitors.9–11
Therefore, we modified the SHFM to apply a hazard ratio of 0.77 for patients treated with an
ACE inhibitor and/or ARB.12 Third, we reduced the treatment benefit of aldosterone
antagonists by replacing the hazard ratio of 0.70 from the Randomized Aldactone Evaluation
Study (RALES) with a hazard ratio of 0.76 from the Eplerenone in Mild Patients
Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF),13 an effect consistent
with an earlier meta-analysis.14
Mode of Death

Author Manuscript

Resource use, associated medical costs, and health-related quality of life in the year before
death differ markedly between patients who die from sudden death versus other causes.15 To
account for these differences, we used mathematical relationships derived from data from
the 4 cohorts described above to estimate the conditional probability of dying from heart
failure, sudden death, or another cause as a function of time and a patient’s baseline SHFM
score (Figure 2). We incorporated these probabilities into the model such that the assigned
cause of death for each virtual patient was conditional on the patient’s initial SHFM score
and simulated time of death.
Modeling Medical Resource Use and Health Utilities

Author Manuscript

In addition to estimating survival and assigning a mode of death for each virtual patient, the
model assigns rates of medical resource use and health utility (ie, quality of life) weights
across time. We used data from Heart Failure: A Controlled Trial Investigating Outcomes of
Exercise Training (HF-ACTION) to estimate relationships between SHFM scores and rates
of medical resource use16 and health utilities.17 As expected, patients with higher SHFM
scores had significantly higher rates of hospitalization, emergency department or urgent care
visits, and nonurgent outpatient visits in the following year.16 We assigned cause-specific
hospitalizations according to distributions observed in HF-ACTION. Similarly, higher
SHFM scores predicted lower health utilities at baseline, and their mean utilities decreased
at a faster rate relative to lower SHFM scores.17

Am Heart J. Author manuscript; available in PMC 2016 November 01.

Reed et al.

Page 5

Modeling Change in SHFM Scores

Author Manuscript

To relate the natural progression of heart failure with corresponding SHFM scores, we used
mathematical relationships to determine the rate at which SHFM scores would have to
increase to maintain consistency with the time-varying global hazard function (Online-Only
Supplement). By quantifying the relationships between initial SHFM scores and SHFM
scores across time, the model updates each virtual patient’s SHFM score each year. This
approach allows the model to assign higher rates of resource use and lower health utilities
over time.
Model Simulations

Author Manuscript

Simulations consist of 10,000 Monte Carlo iterations. Each iteration represents a single
realization of the 2 user-defined virtual patient cohorts with sample sizes specified by the
user. For each virtual patient within a cohort, demographic, laboratory, and clinical
characteristics are sampled from a multivariate mixed distribution based on user-prescribed
inputs. The default values and associated correlation matrix were derived from the 4-cohort
sample of 7151 patients described above (Supplemental Tables B1 and B2).5
For each virtual patient, the simulated time of death is sampled from the corresponding
SHFM score–specific survival function (Supplemental Figure 3.1). The cause of death is
then assigned using the cumulative probabilities of death (for heart failure, sudden cardiac
death, and other cause), conditional on the initial SHFM score and the simulated time of
death (Figure 2). The SHFM score for each virtual patient is then updated for each
subsequent year.

Author Manuscript

Annual counts of medical resources are generated for each virtual patient using negative
binomial regression models, in which the predicted SHFM score at the beginning of each
year is the explanatory variable. When less than 1 year of survival remains, the explanatory
variables in the regression models include the patient’s predicted SHFM score at the
beginning of that year, the simulated cause of death, and the number of days alive in the
final year of life (Supplemental Table 5.1). For each simulated year across the 10,000 Monte
Carlo iterations, unit cost estimates are multiplied by the corresponding counts for each type
of medical resource for each patient in each cohort. Costs in each year are then discounted
and summed to calculate cumulative costs for each cohort.

Author Manuscript

Utility weights are assigned to account for differences in quality of life across patients. Each
virtual patient’s utility weight is a linear function of the patient’s corresponding timeadjusted SHFM score. When the user opts to allow utilities to vary (ie, “stochastic” option),
each virtual patient’s initial utility score is sampled from a normal distribution and then
decays in a linear fashion until the time of death. In cases for which the sampled utility
weight exceeds 1, the value is capped at 1.
Variability
The model incorporates stochastic uncertainty, which represents differences in outcomes
that can occur between 2 realizations of the same patient. For example, a patient with an
SHFM score of 1.0 may have an estimated life expectancy of 5.14 years, but the sampled
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life expectancy for 2 simulated patients with the same SHFM score could be 3 months or 8
years, representing stochastic uncertainty.
The user has the option to select “deterministic” or “stochastic” for SHFM coefficients, time
of death, resource use, and utility weights. With the deterministic option, expected values for
resource use, health utilities, and survival are assigned to virtual patients in each of the
10,000 iterations. With the “stochastic” option, outcomes for each patient are sampled from
their corresponding parametric distributions in each iteration, resulting in 10,000 estimates
for resource use, cost, and survival. Corresponding 95% CIs are calculated by sorting the
10,000 estimates in ascending order and taking the 250th and 9750th ranked values.
Validation

Author Manuscript

We applied the TEAM-HF Cost-Effectiveness Model to 3 heart failure trials to compare
simulated and observed estimates and to demonstrate how the model can be used to reverseengineer a cost-effective disease management program. The inputs specified in each of the 3
validation tests are reported in Supplemental Table D.1. We performed the simulations using
both the stochastic and deterministic options to demonstrate the impacts of these choices.
CHIME
The Medication Adherence in Chronic Illness: Medications, Meaning and Me (CHIME)
pilot study tested an intervention to improve medication adherence in 86 high-risk patients
with heart failure.18 The intervention included quarterly phone calls to the patient from a
nurse. At 1 year, medical resource use and costs were similar across both groups. To
increase the sample size for validation testing, we combined patients from both groups.

Author Manuscript

To demonstrate how the model could be used to evaluate the cost-effectiveness of a disease
management program, we included the 86 patients from CHIME in the standard care group.
Then, we modeled 3 hypothetical scenarios representing programs that could increase
proportions of patients in NYHA class II and increase use of evidenced-based medications.
For program costs in scenario A, we computed the cost per patient per month in CHIME
using the TEAM-HF Costing Tool.4
Internal Validation in HF-ACTION

Author Manuscript

Several statistical associations embedded in the TEAM-HF model were derived from HFACTION.19 Thus, comparisons between estimates from the model with estimates from HFACTION represent an internal validation test. Because observed resource use and outcomes
were similar between groups in the trial, baseline characteristics were pooled across study
groups and modeled over 2 years.
SCD-HeFT
The economic evaluation of the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT)
provides an opportunity to compare estimates over a longer time horizon (20). SCD-HeFT
was a randomized trial of 2521 patients with symptomatic heart failure that found a
statistically significant reduction in all-cause mortality among patients who received a
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single-lead implantable cardioverter-defibrillator (ICD), compared with patients who
received medical therapy or placebo. Median follow-up was 45.5 months.
Funding/Support
Development of the TEAM-HF Cost-Effectiveness Model was supported by grant
5R01NR011873-02 from the National Institute of Nursing Research. The development and
content of the TEAM-HF economic tools are solely the responsibility of the authors and do
not necessarily represent the official views of the National Institute of Nursing Research or
the National Institutes of Health. The trials used for validation purposes were supported
separately.

Results
Author Manuscript

CHIME
In CHIME, patients were hospitalized an average of 1.3 times, had 0.5 emergency
department visits, and had 3.1 outpatient visits (Table 2). By comparison, our model
estimated 1.1 hospitalizations, 1.0 emergency department visits, and 13.9 outpatient visits.
Mean total costs estimated using patient-level data from CHIME were similar to mean total
costs estimated with the TEAM-HF model ($23,861 vs $23,621) when all levels of
uncertainty were varied stochastically. When parameter estimates were modeled
deterministically, the point estimate was $19,622.

Author Manuscript

To evaluate potential disease management programs, we assumed that the intervention in
scenario A increased the proportion of patients with NYHA class II by 10 percentage points
and the use of evidence-based medications increased by 5 percentage points. Intervention
costs in scenario A included initiation costs of $70 and maintenance costs of $59 per patient
per month for 1 year. Compared with standard care, mean total costs in scenario A increased
by $1393 and QALYs increased by 0.2, corresponding to an incremental cost-effectiveness
ratio of $6128 per QALY (Table 3). Scenarios B and C represent a higher-cost program with
$2000 initiation costs plus ongoing costs of $200 per patient per month. With the same level
of effectiveness as scenario A, the incremental cost-effectiveness ratio increased to $64,865
per QALY in scenario B. However, with greater effectiveness in scenario C, the higher cost
of the program is offset by greater gains in QALYs (0.4), resulting in an incremental costeffectiveness ratio of $29,701 per QALY.
HF-ACTION

Author Manuscript

Observed estimates of medical resource use in HF-ACTION and estimates from our model
were similar (Table 4). In HF-ACTION, patients were hospitalized an average of 2.0 times,
visited the emergency department or urgent care clinic 1.6 times, and had 30.6 outpatient
visits. Based on the TEAM-HF model, patients would have been expected to have an
average of 2.1 hospitalizations, 1.9 emergency department or urgent care visits, and 26.3
outpatient visits. Total costs were also similar between estimates based on empirical data
($46,361) and modeled estimates ($48,098). Observed survival at 2 years was 83.4% in HFACTION compared to a modeled estimate of 79.6%.
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Five-year estimates of resource use and total costs generated with the TEAM-HF model
were higher than reported for SCD-HeFT (20) in the ICD and placebo groups (Table 5).
However, the estimated differences in mean costs at 5 years were similar: $23,472 with the
TEAM-HF model and $27,141 in SCD-HeFT. Five-year survival predicted with the model
was 3 to 4 percentage-points lower than reported for SCD-HeFT. Nevertheless, 5-year
survival gains and incremental cost-effectiveness ratios were similar for ICDs compared
with standard care.

Discussion

Author Manuscript

The TEAM-HF Cost-Effectiveness Model provides a flexible tool for the research and
clinical communities to evaluate the long-term cost-effectiveness of disease management
programs in heart failure. In addition to facilitating formal cost-effectiveness analyses, the
model can be used for budget planning, projecting hospitalization rates, and quantifying life
expectancy for a cohort of patients over a time period specified by the user. For example, the
model could be used by health systems to predict cost offsets with a given program or to
demonstrate expected longer-term cost-savings for a payer for a program that increases costs
in the short-term. The model’s flexibility also offers users the opportunity to represent
different perspectives by specifying direct medical costs to represent the health care system
perspective or payments to represent the payer perspective.

Author Manuscript

We believe ours to be the first generalizable simulation model developed to evaluate clinical
and economic outcomes of patient-centered programs in heart failure. Previous models were
developed to evaluate specific interventions and were structured using NYHA class3,21 or
hospitalization counts as health states.22 Such models are not publicly available and cannot
account for a broader range of factors that disease management programs may affect.
Furthermore, variations in methods and reporting hinders the ability to make valid
comparisons across studies.1,23 With repeated use of a common model by different
investigators, a collection of studies could develop to provide a body of evidence on which
types of interventions targeting specific patient groups consistently provide better or worse
value. In addition, individual stakeholders could apply the model to support local decision
making by modifying unit costs, patient characteristics, changes in prognostic variables
affected by an intervention, and the time horizon of interest.
Model Validity

Author Manuscript

It is not possible to simply declare a model as “valid.”24 There are several types of validity,
including face validity, internal validity, cross validity (between models), external validity,
and predictive validity, with the latter 2 types being the strongest. Demonstration of an
economic model’s external and predictive validity, particularly for resource use and costs, is
limited by variations in practice patterns and unit costs across settings.24 Furthermore, for a
model like TEAM-HF that can have multiple applications, numerous validation exercises
across a range of interventions across various patient populations, outcomes, and time
horizons may be necessary. In fields such as diabetes, where multi-application simulation
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models were initially developed more than a decade ago, the relative strengths and
limitations of these models are only now becoming understood.25

Author Manuscript

In our examination of the model’s internal validity, we found that modeled estimates of
resource use and mortality were consistent with empirical estimates from HF-ACTION. The
findings of the 2 external validation tests were also promising. Our modeled estimates of
hospitalizations were similar to CHIME, but modeled estimates of emergency department
and outpatient visits were higher. The discrepancy can be attributed to differences in the
scope of emergency department and outpatient visits included in the analysis. In CHIME,
patients reported emergency department visits and outpatient physician visits associated
with heart failure, whereas the TEAM-HF model includes all-cause visits to all health care
providers (as collected in HF-ACTION). Compared with claims-based analyses in which all
outpatient visits are considered (approximately 14 to 20 per year for patients with type 2
diabetes26; approximately 18 to 22 per year for patients with atrial fibrillation27), the
TEAM-HF model produces counts of similar magnitude.
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SCD-HeFT provided an opportunity to examine the model’s external validity over a longer
time horizon. Cost data were not available in SCD-HeFT over a 5-year time frame for all
patients, and partitioned estimators were used to adjust cost estimates to account for
censoring. Because this approach did not account for higher rates of medical resource use
that occurs with disease progression, one could expect costs from SCD-HeFT to be lower
than costs from the model. Although reported 5-year costs in SCD-HeFT were lower than
predicted with the TEAM-HF model, the CIs from the TEAM-HF model included the point
estimates from SCD-HeFT, and the estimated differences in 5-year survival were similar
between analyses. We believe the 3 sets of validation tests indicate that the resource use,
cost, and survival estimates generated with the TEAM-HF model demonstrate respectable
internal and external validity.
Variability

Author Manuscript

Across the simulations, we generally observed higher point estimates for costs and resource
use when simulations were varied stochastically. This occurs because high counts (ie,
outliers) of resource use are sometimes generated with stochastic sampling, which better
represents empirical distributions of resource use. Thus, we expect that stochastic sampling
will better represent variability that can be expected in real-world situations. In addition,
recognition that costs and survival may substantially vary in cohorts with small sample sizes
is important. The literature includes many small studies of disease management programs
that reported cost savings over a short time period. Such findings could be attributable to
one or more high-cost outliers in the comparison group and would not likely be replicated if
the study was repeated. The TEAM-HF model could be used to evaluate whether observed
differences in resource use, costs, and survival could be expected, given the impact of the
disease management program on the prognostic factors represented in SHFM scores.
Limitations
Although we believe this model could prove to be a valuable resource, its users should be
aware of its limitations. First, because HF-ACTION largely enrolled patients with NYHA
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class II and III heart failure, the statistical relationships between SHFM scores and resource
use and health utilities that are embedded in the model will be less precise for individuals
with more advanced disease. Nevertheless, by integrating end-of-life costs incurred by 339
HF-ACTION participants who died,15 our model incorporates high rates of resource use
incurred during this period. In addition, resource use patterns in HF-ACTION may not be
representative of other settings. Nevertheless, clinical sites in HF-ACTION included both
academic and nonacademic institutions. Users should also recognize that the treatment
effects for medications and devices embedded in the SHFM are based on randomized
clinical trials. Therefore, when proportions of patients treated with evidence-based
medications are modeled, those proportions should represent individuals who adhere to their
treatments at a level similar to what would be observed in a clinical trial, not the proportions
of patients prescribed specific medications. Lastly, although the SHFM offers several
advantages, it does not include some variables found to be predictive of mortality in other
prognostic models, such as B-type natriuretic peptide level.28
We plan to expand the model to incorporate other prognostic models to allow users to
perform sensitivity analyses or choose the prognostic model that includes variables that best
capture the intermediate effects of a given disease management program. In the near term,
we hope that the model proves useful to researchers and health care managers in evaluating
the costs and outcomes associated with disease management programs in heart failure.

Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1.

Survival Curves and Mean Survival Estimates for Integer Seattle Heart Failure Model
Scores
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Cause-Specific Hazard for Death (Upper Panel) and Cause-Specific Probability of Death
(Conditional on Having Died at the Time Indicated by the Time Axis) as a Function of an
Initial Seattle Heart Failure Model Score (Lower Panel)
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User-Defined Inputs for the TEAM-HF Cost-Effectiveness Model
Input Page

Parameters (Options)

General information

Scenario name
Scenario comments
Study design (parallel groups, single cohort, hypothetical)
Group name*
Group sample size*
Length of observation†

Observed resource use and death*†

Counts of cardiovascular procedure-related hospitalizations; medically treated heart failure
hospitalizations; non-heart failure hospitalizations; emergency department visits; outpatient visits
Number of patients who died

Author Manuscript

Clinical characteristics*‡

Age
Sex
Weight
New York Heart Association class
Systolic blood pressure
Ejection fraction
Ischemic failure etiology

Laboratory measurements*‡

Percent lymphocytes
Serum sodium
Total cholesterol
Hemoglobin

Author Manuscript

Uric acid
Diuretics*‡

Proportion of patients receiving diuretics, and daily doses for each of the following medications:
furosemide, bumetanide, torsemide, metolazone, hydrochlorothiazide

Medications and devices*‡

Proportions of patients treated with β-blocker, aldosterone antagonist or potassium-sparing diuretic,
ARB, ACE inhibitor, biventricular pacemaker, ICD, biventricular ICD

Unit costs

Cost per month for β-blocker, aldosterone antagonist or potassium-sparing diuretic, ARB, ACE
inhibitor, diuretic
Cost per event for cardiovascular procedure-related hospitalization, medically treated heart failure
hospitalization, non-heart failure hospitalization, emergency department visit, outpatient visit

Disease management program
characteristics

Time period for intense and maintenance phases of the program
Program cost per patient upon initiation
Program cost per patient per month during intense and maintenance phases of program

Simulation options

Time horizon

Author Manuscript

Discount rates
Select output for resource use counts, costs, survival, and incremental cost-effectiveness ratios
Abbreviations: ACE, angiotensin-converting enzyme; ARB, angiotensin II receptor blocker; ICD, implantable cardioverter-defibrillator.
*

Inputs for both the intervention and comparison groups.
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†

Applies to parallel group design only.

‡

Variables included in computation of Seattle Heart Failure Model scores.
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Author Manuscript
Author Manuscript
Author Manuscript
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Author Manuscript

Author Manuscript

Author Manuscript
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7192 (3320–11,619)
199 (181–216)
660 (440–924)
325 (3014–351)
22,861 (17,357–29,750)

Medications

Emergency department or urgent care visits

Outpatient visits

Total

5379 (3631–7800)

Non-heart failure hospitalizations

Cardiovascular procedures

9104 (6503–13,006)

Heart failure hospitalizations

All-cause hospitalizations

23,621 (8,237–57,535)

1449 (886–2140)

1282 (631–2274)

140 (120–153)

8995 (2750–23,105)

7431 (2272–19,089)

4324 (1322–11,108)

20,751 (6345–53,302)

13.9 (8.5–20.6)

1.0 (0.5–1.8)

1.1 (0.3–2.9)

1198 (733–1770)

87 (43–155)

98 (30–252)

Stochastic*

19,622 (18,093–21,516)

1488 (1426–1557)

1210 (1154–1274)

148 (140–157)

7271 (6658–8040)

6007 (5500–6642)

3496 (3201–3865)

16,774 (15,358–18,548)

14.3 (13.7–15.0)

1.0 (0.9–1.0)

0.9 (0.8–1.0)

1231 (1179–1288)

82 (79–87)

79 (73–88)

Deterministic†

TEAM-HF Cost-Effectiveness Model

Confidence intervals for CHIME were estimated using the bias-corrected nonparametric bootstrap method.

All levels of uncertainty modeled as deterministic except patient profiles.

†

‡

3.1 (2.9–3.4)

Outpatient visits

21,676 (16,139–28,493)

0.5 (0.4–0.7)

Emergency department or urgent care visits

Costs, mean (95% CI), $‡

1.3 (1.0–1.6)

All-cause hospitalizations

All levels of uncertainty modeled as stochastic except unit costs.

*

269 (249–291)

Outpatient visits

Resource use, mean (95% CI)‡

45 (30–63)

109 (84–140)

CHIME

Emergency department or urgent care visits

Hospitalizations

Resource use, total count (95% CI)‡

Outcome

One-Year Estimates of Resource Use and Costs from CHIME and the TEAM-HF Cost-Effectiveness Model

Author Manuscript
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Author Manuscript
—

Program costs

51
38
11

II

III

IV
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5.8 (2.5 to 9.9)
—
4.6 (1.9 to 8.1)
—
—

Life-years

Difference in life-years‡

QALYs

Difference in QALYs‡

ICER, $ per QALY§

Inputs

$6128

0.2 (−0.7 to 1.1)

4.8 (2.0 to 8.2)

0.2 (−0.9 to 1.3)

6.0 (2.7 to 9.9)

1393 (−42,048 to 46,083)

171,672 (141,593 to 203,576)

Results†

Increase 5 percentage points

Increase 5 percentage points

Increase 5 percentage points

Increase 5 percentage points

Decrease 5 percentage points

Decrease 5 percentage points

Increase 10 percentage points

Increase 0 percentage points

$70 initiation plus $59 per patient per month for 12 months

Scenario A*

Dominant – dominated.

Hypothetical program – standard care.

§

‡

Discounted estimates reported.

†

Scenario C*

$64,865

14,742 (−31,180 to 60,044)

185,021 (139,843 to 201,468)

$29,701

0.4 (−0.5 to 1.4)

5.0 (2.2 to 8.4)

0.5 (−0.6 to 1.6)

6.3 (2.9 to 10.2)

15,464 (−29,534 to 59,514)

185,890 (152,506 to 219,375)

Increase 15 percentage points

Increase 15 percentage points

Increase 15 percentage points

Increase 15 percentage points

Decrease 10 percentage points

Decrease 10 percentage points

Increase 20 percentage points

Increase 0 percentage points

$2000 initiation plus ongoing cost of $200 per patient per month

Scenario B*

All levels of uncertainty modeled as stochastic except unit costs. Dominant = less costly, more QALYs; dominated = more costly, fewer QALYs.

*

Abbreviations: ICER, incremental cost-effectiveness ratio; NYHA, New York Heart Association; QALY, quality-adjusted life-year.

—

48

ACE inhibitors

170,279 (139,843 to 201,468)

15

Angiotensin receptor blockers

Difference in costs‡

41

Aldosterone antagonists

Lifetime costs

80

Beta-blockers

Evidence-based medications, %

0

I

NYHA class, %

Standard Care

Variable

Estimated Cost-Effectiveness of Hypothetical Disease Management Programs

Author Manuscript
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79.6 (51.3 – 94.5)

48,098 (19,979–95,799)

2815 (1931–3523)

99.9¶

44,874 (44,180–45,604)

3097 (3073–3121)

2796 (2772–2821)

38,982 (38,332–39,664)

28.9 (28.7–29.2)

1.9 (1.9–2.0)

1.9 (1.8–1.9)

When survival time is modeled deterministically, only 0.1% of patient profiles corresponded to an expected period of survival less than 5 years.

¶

Medication costs were excluded due to costing based on branded medications in HF-ACTION.

Costs updated to 2013 US dollars using the Consumer Price Index for Medical Care and a discount rate of 0%.

CIs for HF-ACTION were estimated using the bias-corrected nonparametric bootstrap method.

||

§

‡

46,361 (42,536–50,856)

Total

2731 (1698–3854)

42,552 (16,291–45,072)

26.3 (18.0–32.9)

1.9 (1.2–2.7)

2.1 (0.8–4.3)

Deterministic†

TEAM-HF Cost-Effectiveness Model
Stochastic*

All levels of uncertainty were modeled as deterministic except patient profiles.

†

2651 (2536–2776)

Outpatient visits

83.4 (81.9 – 84.9)

1763 (1607–1957)

Emergency department or urgent care visits

Survival, % (95% CI)

41,947 (38,210–46,354)

Hospitalizations and physician fees

All levels of uncertainty were modeled stochastically.

*

30.6 (29.3–32.0)

Outpatient visits

Medical costs, mean (95% CI), $‡§||

1.6 (1.5–1.8)

2.0 (1.9–2.1)

HF-ACTION

Emergency department or urgent care visits

Hospitalizations

Resource use, mean (95% CI)‡

Outcome

Resource Use, Costs, and Survival from HF-ACTION and the TEAM-HF Cost-Effectiveness Model

Author Manuscript
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Author Manuscript

Author Manuscript

Author Manuscript
182,460‡

5-year ICER (95% CI), $/life-year saved

0.59

61,489

19.7

1.4

2.7

Placebo

166,571 (65,284–3,653,130)

0.61

122,624 (76,827–179,007)

56.7

3.9

4.0

ICD

0.56

99,152 (50,278–156,255)

55.5

4.1

4.4

Placebo

0.05

23,472 (13,964–31,959)

−1.2

−0.2

−0. 4

Difference

TEAM-HF Cost-Effectiveness Model*

Re-estimated by applying life-years saved (0.149) derived from the 5-year incremental cost-effectiveness ratio reported in Mark et al. (20).

‡

All levels of uncertainty modeled as stochastic.

0.06

27,141

0.8

−0.1

0.1

Difference

Costs reported in Mark et al. (20) updated to $2013 using the Consumer Price Index for Medical Care.

†

*

Abbreviation: ICER, incremental cost-effectiveness ratio.

0.65

5-year survival, proportion

18.9

Outpatient visits
88,630

1.2

Emergency department visits

Total medical costs, mean (95% CI), $†

2.8

ICD

Hospitalizations

Resource use, mean

Outcome

SCD-HeFT Economic Evaluation

Five-Year Estimates From SCD-HeFT and the TEAM-HF Cost-Effectiveness Model
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